Why Does Pharma Validation Still Run on Email Threads and Shared Drives — And Can AI Change That?

Walk into any pharma quality department during audit season and you'll see the same scene playing out. Someone's digging through shared drives looking for a signed protocol from eighteen months ago. Because the systems do not communicate with one another, someone else is manually entering data from a LIMS report into a spreadsheet. A validation engineer is on their third email thread trying to track down who actually approved a change request back in March.

This has nothing to do with science. Fundamentally, validation is meant to provide an answer to one question: does this procedure, system, or product perform as promised in a reliable and safe manner? There is a technological answer to the question. But somewhere along the way, answering it turned into an administrative ordeal — one built on paper trails, disconnected platforms, and institutional memory that lives in people's heads rather than in any searchable system.

Pharma companies have lived with this for so long that it barely registers as a problem anymore. It's just how validation works. ERP handles one piece, QMS another, LIMS and MES cover manufacturing and lab data, and document management systems hold everything else — mostly in isolation from one another. When an inspector shows up, or a change control needs sign-off, someone has to manually stitch all of that together into a coherent, defensible story.

What's changing now is the tooling available to do that stitching. AI-driven platforms are increasingly able to pull relevant records from across these fragmented systems and present them with context — not replacing the judgment of quality and regulatory professionals, but cutting down the hours spent hunting for evidence before that judgment can even be applied. The approval still sits with a human. What's different is how fast they can get to a decision, and how solid the trail looks when someone asks them to defend it later.

This matters because regulators haven't slowed down. The definition of "compliant" is becoming increasingly specific in FDA guidelines, ICH standards, and GAMP 5 frameworks, especially with the introduction of AI tools. That pressure will be felt by organizations that continue to view validation as a yearly fire drill. The ones building traceability into daily operations — so the evidence is already organized before anyone asks for it — will have an easier time keeping up.

None of this changes what validation is for. It still exists to prove that pharmaceutical products and processes work the way they're supposed to. What's finally shifting is how much of that proof has to come from manual effort versus systems that were actually built to track it.